Allergy pioneers

Breaking new ground

With almost 100 years of experience, nobody knows allergy like us.

In the fight against allergy, science leads the way, and ALK has spent nearly a century pushing back the frontiers of knowledge with the aim of helping people to take control of their allergy and their life.

Our understanding of how allergy works has helped us to develop a range of allergy immunotherapy treatments, which form the core of our current product range.

Every year, we invest millions of euro in further research and development activities. Our current R&D focus is on completing and commercialising our portfolio of sublingual allergy immunotherapy (SLIT) tablets for the five most important allergens, and for all relevant ages.

Investing in understanding and innovation

Treatments for five of the most common allergies
We are developing a portfolio of SLIT-tablets covering five of the world’s most common respiratory allergies – house dust mite, grass, trees from the birch tree family, ragweed and Japanese cedar – for adults, adolescents and children.
Evidenced-based treatment
Allergy immunotherapy has come a long way since it was first discovered. Our latest, tablet-based treatments have been tested in multiple clinical trials involving more than 20,000 people and have the largest evidence-base of any form of AIT treatment.
Ground-breaking clinical trials
The programme of clinical trials for our SLIT-tablet portfolio has established important evidence about the utility, effectiveness and longevity of treatment with allergy immunotherapy.
Last updated: 2019.07.05